Efficacy and Safety of PF-00299804 (PF299), an Oral, Irreversible, Pan-human Epidermal Growth Factor Receptor (pan-HER) Tyrosine Kinase Inhibitor (TKI), as First-Line Treatment (tx) of Selected Patients (pts) with Advanced (adv) Non-Small Cell Lung Cancer (NSCLC)
Refereed conference paper presented and published in conference proceedings


Full Text

Other information
All Author(s) ListMOK Shu Kam Tony, SPIGEL R D, PARK K, SOCINSKI A M, TUNG Y S, KIM D, BORZILLO G, ZHANG H, OCONNELL P J, JANNE A P
Name of ConferenceASCO Annual Meeting 2010
Country/Region of ConferenceUnited States of America
Proceedings TitleASCO Annual Meeting 2010
Detailed descriptionorganized by American Society of Clinical Oncology,
Year2010
Month6
Place of PublicationUnited States of America
Pages7537
LanguagesEnglish-United Kingdom
KeywordsPF299; pan-HER; NSCLC

Last updated on 2018-18-01 at 16:47